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1. Introduction
Among neurodegenerative diseases, dementias are an heterogeneous group in terms of their
symptoms and pathological findings. One of the main risk factors for developing neurodege‐
nerative disease is aging. Currently there is no cure for these diseases, mainly due to the lack
of knowledge of the causes and mechanisms of the accumulation of abnormal protein aggre‐
gates within the cellular or extracellular body. This is a common characteristic pathological
feature in several neurodegenerative diseases. Pathological protein accumulations not only
define the characteristics of a particular neurodegenerative disease, but also are associated
with clinical progression, including cognitive impairment or motor disorders [1].
Research in this field had been focused on finding potential highly specific biomarkers that
correlates with the disease and can be detected at early stages of the pathology. In medicine,
a biomarker is defined as a featured specific somatic or measurable biological change related
to a health condition or disease [2]. A biomarker can be measured and objectively evaluated
as an indicator of normal biological processes or disease, as well as the pharmacological
response to treatment. In general, we can say that a biomarker can be used to diagnose the
disease, or to establish its severity and allow monitoring its progression and response [1, 3, 4].
A biomarker must adhere to the following statements: 1) detect a fundamental feature of the
neuropathology of the disease, 2) must be validated in cases confirmed by neuropathological
examination, 3) have a high sensitivity and specificity, above 80% for discriminating the
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neuropathology in question, 4) must be reliable. [3] In clinical studies, the biochemical analyse
of cerebrospinal fluid, plasma and urine, constitute the preferred samples to search for
biomarkers [5]. On the other hand neuroimaging studies and detection of genetic markers are
also useful for tracking the progression of the disease [6-8]. However, these studies remain in
an experimental phase and need to be further investigated. The challenge is to find the
correlation between the biomarker expression, the cognitive decline and the onset of the
neuropsychiatric symptoms. It is also important to emphasize that the diagnosis of neurode‐
generative diseases is mainly clinical and in most of the cases it is done when the dementia
syndrome has already been established. To this day, the more accurate confirmation of the
diagnosis is the post-mortem pathological study. This greatly limits the early therapeutic
interventions. Optimally, it is expected that biomarker studies will focus at four levels: 1)
biomarkers of risk, which will help identify risk populations with mutations or changes in
gene sequence, 2) diagnostic biomarkers in the early differential diagnosis would be useful to
confirming the occurrence of the neurodegenerative disease, and thus allow the possibility of
an early therapeutic intervention. An example of this type of biomarker approach are the
neuroimaging studies, associated with the positron emission tomography, taking into
consideration the measurement of the degree of atrophy of the cortex, the amplitude of the
ventricles, as well as of hippocampus, 3) biomarkers of progression, these markers could
predict the evolution of the disease. Finally, 4) neuropathological-molecular biomarkers are
the abnormal neuropathological lesions that constitute the features of the disease. For example,
the abnormal processing and deposits of hallmark proteins (such as of tau protein, amyloid-
β peptide and α-synuclein) of neurodegenerative diseases.
In this chapter we will focus on the description and abnormal processing of tau protein,
amyloid β peptide and α-synuclein, and its implication as specific biomarkers of neurodegen‐
eration. First we will talk about abnormal processing and pathological aggregates of tau
protein. The group of diseases characterized by abnormal tau processing and deposits, are
known as tauopathies. Tauopathies include fronto temporal dementia (FTD), progressive
supranuclear palsy (PSP), neurofibrillary tangle-predominant dementia (NFTD) and Alz‐
heimer's disease (AD); these neurodegenerative diseases are characterized by the presence of
neurofibrillary tangles (NFTs), consisting of paired helical filaments (PHFs). These filaments
are mainly comprised of tau protein, and constitute specific markers of this kind of neurode‐
generation. Better understanding the process that lead to protein aggregations and its abnor‐
mal processing in pathological conditions, could improve the differential diagnosis and would
allow tracking the progression of the neurodegenerative disease.
2. Alzheimer's disease
Alzheimer's disease (AD) is the most common cause of dementia in older adults. Characterized
for a severe cerebral atrophy that is associated to the presence of two types of structures, the
neuritic plaques (NPs) and neurofibrillary tangles (NFTs). The density of these structures
correlates with the clinical state of dementia and their presence offers a definitive diagnosis of
AD at post mortem.
Neurochemistry356
2.1. Neuritic plaques
NPs, that could be found in normal aging brain, but in lower amount (approximately 1000
times less that in AD), are composed of a core of β amyloid fibrils (Aβ) closely associated with
dystrophic neuritis distributed to the periphery of the amyloid core (Fig 1A). The biological
Aβ peptide is a product of Amyloid precursor protein (APP) processed by several proteases
(Fig 2).
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Figure 1. Histopathological lesions of human brain with dementia. A, B) Alzheimer´s disease, C) Pick’s dementia, C)
corticobasal degeneration D) progressive supranuclear palsy neurodegeneration. Triple inmunolabelling with anti‐
bodies raised against phosphorylated tau protein. A) neuritic plaque, amyloid beta peptide is evidenced by thiazine
red dye, this dye recognized extracellular deposits of Aβ fibrillar. The dystrophic neurites are evidenced by antibodies
raised against phosphorylated tau protein. B) Neurofibrillary tangles, evidenced by antibodies raised against phos‐
phorylated tau protein at Thr231 (green channel) thiazine red (red channel) and phosphorylated tau at Ser396 (Blue
channel). C) Pick Bodies in neuronal cells (Molecular layer of hippocampus) are detected by antibodies against phos‐
phorylated tau protein at Thr231 (green) and phosphorylated tau at Ser396 (blue), thiazine red did not have affinity to
this accumulation of tau protein. C) Ballooned neurons. Immunoreactivity to antibodies raised against phosphorylated
tau at Thr231 (red channel), and tau pSer396 (blue channel). The expression of truncated tau protein at Asp423 (de‐
tected by antibody TauC3) showed a weak staining in a doted patter in the NFTs (green Channel). D) Immunureactivity
of oligodendroglial coiled bodies and tufted astrocyes to phosphorylated tau protein at Ser202 and Ser205 (AT8 anti‐
body, green channel) and phosphorylated tau at Ser396 (blue channel). Thiazine red showed a strong affinity for ac‐
cumulations of tau protein in astrocytes and microglia.
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Figure 2. Processing of amyloid precursor protein. A) APP processing is the starting point of the formation of amyloid
plaques. APP is a transmembranal protein that is processed by a series of proteolytical enzymes, releasing several frag‐
ments among themis the Aβ fragment that is released into the extracellular space which accumulates and forms amy‐
loid-β plaques. B, C) APP processing to generate sAPPa fragment. C) non-amyloidogenic pathway of APP processing by
α-secretase, generating a fragment called sPPAα, which is secreted into the extracellular space, subsequently proteo‐
lyzed by γ-secretase fragment remains in the membrane, leading to a small fragment called p3. D-E) amyloidogenic
pathway. Alternative processing of APP, which generates the amyloid-β peptide, initiated by β-secretase, releasing a
fragment called sPPAβ, being liberated into the extracellular space, the γ-secretase subsequently proteolyzed a frag‐
ment that is enclosed within the cell membrane releasing amyloid-β fragment into the extracellular space, that later
could form amyloid-β plaques.
3. Amyloid precursor protein
The amyloid precursor protein (APP) is a type I transmembrane glycoprotein of approximately
120 kDa. APP has several isoforms derived from differential splicing, where the predominant
variants are APP695, APP770 APP751(the numbers correspond to the number of amino acids
(aa.) in each isoform). These three isoforms have in common the transmembrane region and
the intracellular domain, however, in the brain, APP695 is the predominant APP specie present
in neurons, while APP770 and APP751 and are primarily expressed in glial cells [9].
The human gene encoding APP, is located on chromosome 21, and was first identified in 1987
[10]. More than 76 mutations have been identified in APP, that cause the inherited form of AD
and a related condition hereditary known as cerebral amyloid angiopathy. These mutations
consist in amino acid substitutions within or adjacent the Aβ domain. However, even though
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APP mutations are found only in rare cases of AD, they are important because they provide
evidence that Aβ and APP play a central role in the pathogenesis of AD.
The APP is mainly located in the cell membrane, but has also been localized in the trans-Golgi,
endoplasmic reticulum (ER) and endosomal and lysosomal membranes [11]. Aβ peptide
release occurs where the secretase complex is precent and, therefore, is likely to be produced
in various cell compartments. Most tissues and cells has the enzymatic machinery necessary
to produce and degrade Aβ. This suggests that the production of Aβ from APP has a normal
biological function. Since the discovery of the APP, a number of physiological functions have
been attributed to this molecule, some of them unique to certain isoforms, but their actual
functions remain unclear. It is important to mention that a number of functional domains have
been assigned to the extracellular and intracellular APP regions. Most of these domains are
binding sites for metals (copper and zinc), extracellular matrix components (heparin, collagen
and laminin), neurotrophins and adhesion molecules, and protease inhibition domain (the
protease inhibitor domain Kunitz present in the isoforms APP751 and APP770) [12].
APP processing by the complex of secretase enzymes, occurs thru two pathways: The non-
amyloidogenic (Fig. 2 B, C) and amyloidogenic (Fig. 2 D, E). In the non-amyloidogenic
pathway, APP is cleaved by the α-secretase, a membrane-associated zinc metalloprotease that
belongs to the ADAM family (an enzyme in the family of metalloproteases and disintegrins
such as ADAM9, ADAM10 and ADAM17). The cleavage by α-secretase occurs at amino acid
position 83, counting from the carboxyl terminal domain of APP, where is a large ectodomain
called sPPAα which is secreted into the extracellular milieu [13]. The resulting fragment of 83
amino acids, known as C83, is retained in the membrane and subsequently cut by the γ-
secretase, resulting in a shorter fragment called p3, which is considered non-amyloidogenic
although it is deposited in diffuse plaques [14]. The γ-secretase has been identified as an
enzyme complex comprised of presenilin 1 or 2 (PS1 and PS2), nicastrin, APH-1 (anterior
pharynx defective 1) and PEN-2 (presenilin enhancer 2). Importantly, the cleavage made by
α-secretase occurs within Aβ sequence, between residues 16 and 17, which excludes the
formation of this peptide (Fig. 2 B, C).
The amyloidogenic pathway is an alternative processing for APP resulting in the generation
of Aβ. Initial proteolysis is mediated by β-secretase, the enzyme known as BACE1 (β-site APP-
cleaving enzyme), at aminoacid position 99, counting from the C-terminus. This cut results in
the release of a fragment called sPPAβ to the extracellular space and leaves the fragment C99
within the membrane, and generates the amino terminus for Aβ[15]. Subsequently, γ-secretase
cuts at different points of the carboxyl terminus of the Aß, between amino acid residues 38 and
43, finally releasing the Aβ peptides [16]. (Fig. 2 D and E).
4. Β-amyloid peptide
Most of the secreted Aβ peptide consist of 40 amino acid residues (Aβ40), while a small
proportion, about 10%, comprise 42 amino acid residues (Aβ42) [11]. Because Aβ42 is more
hydrophobic, aggregates rapidly and is more prone to form fibrils, which explains why this
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isoform is predominantly found in brain plaques of AD patients. Historically, Aβ (1-40 aa.)
and Aβ (1-42aa.) are the the main focus of research in the neurodegeneration field, because
they are the most frequently found in NPs of AD brains. However, it is well established that
Aβ truncated or modified forms at the N-and C-terminus are also present in AD brains. The
Aβ C-terminus truncation may be due to the action of different γ-secretases. Furthermore, it
has been confirmed a greater heterogeneity of species of Aβ truncated at the amino terminus
in the core of the NPs [17].
5. N-terminal truncated species of amyloid β
The loss of the hydrophilic part located at Aβ amino terminus increases the hydrophobicity of
this peptide, which favors their propensity to aggregate and deposit. It has been proposed that
Aβ species truncated at the N-terminus play an important role in the pathogenesis of AD. In
this respect, with mass spectrometry it has been identified in NPs, besides isoforms 40 and 42,
two other peptideswith truncations at the amino terminus, one in the amino acid 3 of Aβ (3-42
aa.) and another at amino acid residue 11 of Aβ (11-42 aa.), with relative molecular masses of
4.2 kDa and 3.5 kDa, respectively [17]. Other in vitro studies have shown that a small increase
in the physiological production of these species may be sufficient to trigger the formation of
neuronal processes which induce changes in cytoskeletal proteins, moreover, It has been
proposed that these amino-terminus truncated Aβ peptides might act as a center of aggregation
of other Aβ neurotoxic species, that predominate in the core of the NPs [18]. Truncated species
may be generated from APP through alternative processing by the BACE enzyme or produced
from the full-length Aβ peptide (1-42 aa.) by extracellular amino peptidases. It is known that
two isoforms of BACE are involved in the production of Aβ: BACE1 and BACE2, however it
is established that the main neuronal protease BACE1 is required to cut an APP in sites 1 and
11 of the Aβ peptide. BACE1 is a transmembranal glycoprotein type I, that exhibits all the
Properties of β-secretase. For example, the optimum pH is slightly acidic, is located in cell
compartments where Aβ is generated, and cleaves APP in the β cleavage site with a high
affinity for the swedish APP (swAPP), which is a mutated APP, associated with familial AD,
known to increase the production of Aβ. Finally, BACE1 is present in the secretory cells (i.e.
microglia) of Aβ and is highly expressed in neurons.
6. Aggregation of amyloid β
A common feature among several neurodegenerative diseases is that some mutations associ‐
ated to them, lead to the expression of protein variants with an increased tendency to aggre‐
gate. Thus, conformational changes and aggregation of Aβ peptide are central features in AD.
Currently, there is evidence that Aβ monomers are not toxic to the cells and have a protective
effects on neurons against oxidative stress [19]. However, there are many reports that indicate
that the oligomers of Aβ, also known as soluble oligomeric ligands of amyloid-β peptide
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(ADDLs) could be even more toxic than Aβ fibrils. The ADDLs mediated toxicity was described
by Klein and colleagues, which found that the oligomers cause neuronal death in hippocampal
slices at nanomolar concentrations [20].
The polymerization of Aβ monomers in the extracellular space of the brain appears to correlate
with the presence of metals [21]. These same metals may generate reactive oxygen species
(ROS), oxidative stress-producing agents. Iron, for example, is in the NPs. This could indicate
that this metal has a toxic effect due to the promotion of ROS, but could also promote Aβ
assembly [18]. It is known that transition metals produce oxidative stress through the gener‐
ation of reactive oxygen species (ROS) and recently was noted that the presence of these metals
may be related to the polymerization of the monomers of Aβ in the brain neuropil space [21].
Thus iron in NPs, seems to have toxic effects because it promotes the formation of ROS as it
enhances Aβ assembly [18].
7. Tau protein – AD brains
7.1. Normal tau
The interaction between the microtubule motor proteins and microtubules is regulated by tau
protein, which operates and controls the movement of axonal organelles such as mitochondria
and vesicles favoring the function and viability of neuronal cells [22] (Fig 3A). Proline-rich
region at the N-terminus, interact with proteins containing an SH3 domain and with FYN
tyrosine kinase. FYN interaction is highly relevant for routing toward the postsynaptic region,
since this kinase phosphorylates the NMDA receptor 2B subunit [23]. This phosphorylation
enables interaction of NMDA receptor with the postsynaptic density protein 95 (PSD95) and
this interaction is required for the excitotoxic signaling[24].
Two main regions characterize the tau molecule, the N-terminal portion that accounts for two-
thirds of the molecule, and the proline-rich region. The N-terminus region is subdivided into
two subregions: one acidic, which has been proposed as a possible binding site for metals [25].
The other region is the proline-rich region. This site has a high amount of amino acids
potentially susceptible to phosphorylation and appears to be important for the binding of tau
to microtubules [26]. Other important regions in tau protein are: the microtubule binding
domains including the repeats 3 or 4 with 31 or 32 aa's. and theC-terminal region, that also
contains a proline rich region and an acidic region (Fig 3).
tau is encoded by a single gene located on chromosome 17q21. The gene has 16 exons, in which
through alternative splicing 6 isoforms are generated in the Central Nervous System (CNS).
These isoforms vary in length by including exons 2, 3 and 10, with a maximum length of 441
amino acids in the largest protein isoform. In sporadic AD, no mutations of the tau protein
have been reported.
The tau protein is susceptible to posttranslational modifications that have direct effects on their
function (Fig. 3B). The most important modification is the phosphorylation of certain residues
that regulate microtubule binding. The coordinated activity of kinases and phosphatases
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regulate the phosphorylated state of the protein, which decreases when the level of phosphor‐
ylation promotes microtubule binding. Otherwise, the increased phosphorylation of the
protein in these residues facilitates disassembly of the microtubule. tau protein has 85 potential
phosphorylation sites, of which a large amount is not involved in the normal regulation of its
association with microtubules [27].
tau protein may undergo other posttranslational modifications such as glycosylation, nitration,
poliamination, ubiquitination and SUMOlyzation [28], which role is not well understood.
These changes seem to be more involved in the deregulation of the normal function of the tau
protein favouring other effects such as loss of function and promotion of abnormal aggregation
characteristic of the large group of diseases with tau alterations (tauopathies), including AD.
7.2. Abnormal post-translational modification of tau
Several studies have confirmed the importance of tau abnormalities as a mechanism that
alters  its  microtubule  binding  capability,  and  promotes  abnormal  aggregation  [29,  30].
Phosphorylation is  a major post-translational  modification of  tau that  regulates microtu‐
bule binding and release. Tau protein is equipped with 85 phosphorylation sites, 45 serines,
35  threonines,  and  5  tyrosines  [28].  Increased  phosphorylation  reduces  its  affinity  for
microtubules,  resulting in disruption of the cytoskeleton, particularly phosphorylation at
threonine 231 and serine 293, 324 and 356. It has been described 30 phosphorylation sites
related to AD. In vivo, the kinases that are more associated with tau phosphorylation are
glycogen synthase kinase-3β (GSK3β), cyclin-dependent kinase 5 (CDK5) and the microtu‐
bule-affinity regulating kinase (MARK) [28, 31].
1 2 3 4
1 45 103 441
391
423
p‐S 396
DMR
N C
231
p‐231
TG3
199, 202, 205
AT8
5‐15,312‐322
Alz‐50
T‐46MI9
TauC‐3
421
AT100
199, 202, 205‐ 212,214
Alz‐50
Figure 3. Schematic representation of the functional domains of the longest tau isoform. The projection domain, in‐
cluding an acidic and a proline-rich region, interacts with cytoskeletal elements between microtubules in axons. The
N-terminal region is also involved in signal transduction pathways by interacting with proteins as PLC-γ and Src-kinas‐
es. The C-terminus part, referred to as microtubules binding domain, regulates the rate of microtubules polymeriza‐
tion. In this schematic diagram it is depicted the site were some tau antibodies specifically recognize tau protein
epitopes.
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Kinases that contribute mainly in the abnormal phosphorylation of tau protein are: GSK3β,
CDK5 and MARK. In AD and other tauopathies an alteration in the expression or in the activity
of these kinases has been reported [32, 33].
Moreover, tau protein is a substrate for various proteases such as calpain, caspase 6 and
caspase-3,  shown  by  in  vitro  experiments  [34,  35].  However,  this  effect  has  not  been
recognized as a normal mechanism and it has been proposed that endogenous proteoly‐
sis contributes tau aggregation process and abnormal toxicity. The most relevant trunca‐
tions in AD are those occurring in the Asp421 and Glu391 of tau C-terminus [34, 36-38].
There is controversy about the genesis of these truncations, and it has even been postulat‐
ed that they are mutually exclusive, but occur in a continuous process along AD porogres‐
sion  [39-41]  and  contribute  to  the  formation  of  NFTs  [40].  Moreover,  it  has  also  been
proposed  that  such  truncations  occur  very  early  in  the  disease  and  do  not  necessarily
participate in tau assembled, thus these truncations can be observed in the unassembled
amorphous aggregates of tau protein [42]. Notwithstanding these studies it has been found
that there is a pathological effect of these truncations, reflected in an increased cytotoxici‐
ty when they are overexpressed in cultured neuronal cells in vitro. Finally, the accumula‐
tion of these truncated forms in brain tissue of subjects with AD, seems to correlate with
AD clinical diagnosis and progression [40], which makes the truncation of tau protein an
important biomarker in the diagnosis AD.
The truncated form of tau protein in the Glu391, is characterized as a 12 kDa fragment, with a
length of 92 to 95 amino acids corresponding to the region of the microtubule binding domain.
This fragment is known as paired helical filament minimum core (PHFcore) [43]. tau PHFcore
has high affinity for the intact tau protein. The association of tau full length with the PHF core,
triggers a molecular mechanism of phosphorylation and subsequent truncations that could
induce the formation of a new tau fragment truncated at Glu391 that would have affinity for
more intact tau molecules, thus inducing phosphorylations and truncations of these intact full
length tau molecules, self-propagating this capture-breaking process generating more
aggregated PHFcores that forms stable insoluble filaments [36]. The PHFcore fragment is
recognized by antibody 423 [44]. So far the PHFcore seems to be the only peptide whose
cytotoxicity has been demonstrated by Fasulo et al [45], in COS cells co-transfected with the
cDNA of full length tau protein and the sequence for the PHFcore, reporting that these cells
died by apoptosis. This showed the high toxicity of tau truncated at Glu391. This finding in a
cell model, together with molecular neuropathology studies, which showed that tau truncation
at Glu391 correlates with AD pathology and other tauopathies, suggests that this PHF core
could be used as an accurate marker for this type of neurodegenerative disease. This type of
propagation of the pathological tau specie (PHFcore), resembles prions disease “infectious
process”, thus modified tau could induce pathological changes in normal tau, which in turn
would modify more normal tau molecules. This new approach to understanding AD pathol‐
ogy in terms of protein seeding had been proposed by several groups [46-48], however, since
1993, the group of Novak [43], had already called the PHFcore as "tauon", considering its prion
like behaviour.
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Glycation is a non-enzymatic glycosylation observed during aging, and its modified products
cannot be degraded or eliminated by the normal clearance mechanisms. These products also
contribute to the generation of free radicals. tau is a substrate of glycation and this modification
increases the capability of tau to form aggregates and stabilize the formation of polymers of
this protein [49]. O-GlcNAcylation may regulate phosphorylation of tau in a site-specific
manner. Moreover O-GlcNAcylation at Ser356 greatly slows down the aggregation speed of
tau and also reduces its phosphorylation by GSK3β and CDK5 [50].
Other dementias known as tauopathies, such as Pick's disease, hereditary frontotemporal
dementia with Parkinsonism linked to chromosome 17, sporadic corticobasal degeneration
and progressive supranuclear palsy, are also associated with post-translational modifications
of tau protein. In these neurological disorders, it has been described that tau protein is
aggregated in characteristic lesions that include pick bodies (Fig 1D), the NFTs, granulo-
vacuolar degenerations, the threads of neuropil, and dystrophic neurites. In most of these
lesions, it has been reported that tau protein undergoes the same posttranslational modifica‐
tions that occur in AD, mainly hyperphosphorylation at various domains [51]. However, in
other diseases characterized by the presence of filamentous tau protein, known as tauopathies,
several mutations of this gene occur, mainly the P301L mutation, which is associated with the
frontotemporal degeneration with parkinsonism linked to chromosome 17 (FTLD17). This
mutation is the most widely studied in various in vivo models [52]. Apart from mutations, there
are truncations in tau protein that are associated to this disease, such as endogenous truncation
and mainly the C-terminus truncation at the Asp421 [51].
8. α-synuclein and Parkinson's disease
In elder adults, Parkinson's disease (PD) is a major cause of movement disorders. This disease
is characterized by loss of dopaminergic neurons of the compact substantia nigra, which results
in lowering of dopamine in the striatum. PD belongs to a group of neurodegenerative disorders
called Lewy bodies diseases (ECL) [53] (Fig 1 C). The major components of Lewy bodies are
aggregates of filamentous α-synuclein (αS) protein (Fig 5C). The human α-S is a 140 amino
acid protein. This protein consists of three regions: an amphipathic N-terminal (amino acids
residues 1-60), non-β-amyloid component (NAC) hydrophobic central region (amino acids
residues 61-95) and an acidic C-terminal region (amino acids 96-140) [54].
αS belongs to the family of Synuclein included beta-synuclein (β-S), and γ-synuclein (γ-S) [54].
The Synuclein genes are highly conserved between species. Synuclein family was found in
vertebrates and has never been observed in unicellular organisms. In invertebrates it has been
observed an homologous to the synuclein protein.
With regard to the normal function of the αS, little is known. However, it is reported that αS
is expressed at high levels in the brain, specifically associated to neurons, and also has been
observed expression in other tissues such as hematopoietic cells. αS can be associated to lipids,
in neurons it has been observed associated with synaptic vesicles modulating its activity,
suggesting that under normal conditions αS could be involved in various functions associated
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with neurotransmission and synaptic plasticity [55]. Also, it was shown that αS participates
in synaptic plasticity during development and learning [54] and in the regulation of synaptic
vesicle mobilization in nerve terminals [56].
Immunostaining with antibodies recognizing αS in normal human brain, shown a diffuse
pattern in the neuropil-like synaptic region. However, in PD brains, αS immunoreactivity is
also strong in some of the Lewy bodies and neuronal processes [57]. Currently, ubiquitin
immunostaining and eosin staining, are the most widely used technique to demonstrate Lewy
bodies in PD brains. Biochemical studies have shown that αS is the most abundant protein in
Lewy bodies and it is located in the fibrous material contained in this structure. αS pathological
deposits are less soluble than the normal synuclein. This is possibly due to posttranslational
modifications such as truncations, nitrations, and phosphorylations, ubiquitination. αS
undergoes pathological modifications in PD. It should be emphasized that although αS is a
neuropathological marker of PD as well as dementia with Lewy bodies (DLB), there is no
evidence that αS is related to the cause of these disease.
In vitro studies suggest that the hydrophobic region of αS NAC is essential for the aggregation
and toxicity of the molecule [58]. This region is partially absent in β-Synuclein (βS), which may
explain why the βS has a low ability to auto-aggregate and form oligomers and fibrils [59, 60].
Hashimoto et al (2001), demonstrated, that βS interacts with αS and it is capable of preventing
αS aggregation in vitro and in vivo [59]. In vitro studies have shown that βS by itself tends to
associate strongly with αS to form aggregates [61][58]. Studies suggest that the aggregates are
formed from intermediate forms (with unchanged conformation) partially folded structures,
which would give rise to the fibrils. Previous structures of these fibrils are oligomers and
annular protofibrils forming pore-like structures [62]. However, the mechanisms by which
they form oligomers and then fibrils are not yet understood.
Some changes in αS protein are posttranslational, which have been associated with a role as
mediators of the cytotoxicity of this protein.
Furthermore, the pathological αS is characterized by phosphorylation at Ser129 which is
detected  by  immunohistochemistry  in  Lewy  bodies  in  PD  human  brain.  The  Kinase
responsible  for  this  phosphorylation  is  casein  kinase  II  and GRK2/5,  which  phosphory‐
lates αS in vitro. Originally, the Ser129 phosphorylation was found in a Drosophila model,
which generated a pseudophosphorilation (S129A) from the regular αS. This modification
resulted in a tendency to intracellular accumulation of  this protein (αS),  compared with
wildtype organisms. This change was not associated with any toxicity, olthough this still
is  controversial  and it  is  need to clarify the role of  phosphorylation at  Ser129 αS in the
molecular pathology of PD.
The truncation of αS has been associated with its high capacity of aggregation. Ttransgenic
mice expressing truncated αS have substantial cell loss especially in the brain. Truncated
species of αS were found in the lysosome suggesting its proteolysis in these organelles,
nonetheless α-synuclein is also a substrate for cytoplasmic calpains [57].
In  the  pathogenesis  of  diseases  with  Lewy Bodies,  interactions  between β-amyloid pro‐
tein and αS are crucial. For example, Aβ worsens associated deficit coused by αS accumu‐
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lation and also promotes oligomerization of αS [63]. It has also been demonstrated that in
pathological  conditions  both  aggregates  of  αS  and  Aβ,  are  membrane-associated.  It  is
suggested  that  lipid  rafts  can  be  a  suitable  site  for  abnormal  interactions  between  the
aggregated forms of  α-S and Aβ.  These aggregated forms are  also described in various
intracellular membranous structures [59].
To elucidate how the interactions between αS and Aβ influence its aggregation properties, in
vitro studies were done. Evidence, demonstrated that β-amyloid promotes αS aggregation in
vivo, on the other hand, in APP transgenic mice, it was observed an accumulation of αS.
Therefore, It was hypothesized that β-amyloid, αS, and tau protein promote the accumulation
of each other [64], in recent years, there have been a number of studies that support this
hypothesis.
The αS has become one of the key proteins in the aetiology and pathogenesis of some of the
most common neurodegenerative diseases, such asPD.
It is suggested that the Lewy bodies (LB) constitute an histpopathological marker that
correlates with the onset of symptoms of dementia. In 10-20% of the cases of dementia with
LB it is observed also the presence of NFTs and NPs at Braak stages V and VI, suggesting that
this type of neurodegeneration could share pathologic features with AD. The molecular
analysis of LB in PD and dementia associated with Parkinson's disease are indistinguishable,
however the difference is based on the localization of these lesions. Using double immunos‐
taining it is possible to observed the presence of epitopes of phosphorylated and non-phos‐
phorylated tau protein, in the periphery of the LB or colocalizing with these structure and with
αS aggregates. in vitro studies had shown that alpha synuclein preformed fibrils may promote
the formation of fibrils of phosphorylated recombinant tau protein, that is insoluble and
thioflavin-S positive.
9. Taupathies
The Tauopathies are classified according to the predominant species of tau that accumulates:
tau proteins containing 3 (3R) or 4 repeats (4R) of microtubule binding domain. In Pick's disease
(PiD), 3R tau predominates, whereas 4R tau is characteristic of corticobasal degeneration (CBD)
and progressive supranuclear palsy (PSP) [65].
PiD is the least common FTLD-tau characterized by neuronal Pick bodies in a stereotypic
neuroanatomical distribution. PSP and CBD are more common than PiD and have extensive
clinical and pathologic overlap, with no distinctive clinical syndrome or biomarker that
permits their differentiation. The hallmark’s to diagnosis rests upon postmortem analysis of
the human brain and demonstration of the presence of tangles, oligodendroglial coiled bodies
and tufted astrocytes in PSP or threads, pretangles and astrocytic plaques in CBD. The
anatomical distribution of tau pathology determines the clinical presentation of PSP and CBD,
as well as PiD
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10. Pick´s disease
In Pick's  disease the first  symptoms occur in emotional  and social  functioning.  It  is  the
mood changes, often biased towards euphoria, disinhibition and deterioration in social skills
that are so noticeable. Pick's disease generally occurs between the ages of forty and sixty
years of age. In PiD brain tissue changes and neuronal loss occurs in focal areas rather than
the generalized damage of Alzheimer's. Pick's disease affects the frontal and temporal lobes
of the brain. Marked shrinkage, called atrophy, of the frontal lobes of the brain occurs that
can be seen on brain scans. Pick's disease is marked by the presence of abnormalities in
brain cells called Pick's bodies. These are found in the affected areas as well as elsewhere
in the brain. Pick's bodies are fibres that look very different from the neurofibrillary tangles
found in Alzheimer's disease. Pick's bodies are straight rather than paired and helical. Pick
bodies, are characterized by the presence of distinct argyrophilic (silver staining) spheri‐
cal  inclusions called Pick bodies and globose neurons.  Pick bodies are composed of  tau
protein enriched in 3R tau, which can be evidenced with biochemical studies [66] or more
recently with antibodies specific to tau isoforms. Mondragon-Rodriguez et al (2008) [51],
conducted  an  immunohistochemical  study  and  confocal  microscopy  analysis  of  brains
section of Pick body dementia, and showed phosphorylation epitopes and conformational
changes of tau protein that are described in AD.
11. Cortico basal degeneration
CBD is a progressive neurological disorder characterized by neuronal cell loss and atrophy
(shrinkage) of multiple areas of the brain including the cerebral cortex and the basal ganglia.
CBD progresses gradually. Initial symptoms, which typically begin at or around age 60, may
first appear on one side of the body (unilateral), but eventually affect both sides as the disease
progresses. Symptoms are similar to those found in Parkinson disease, such as poor coordi‐
nation, akinesia (an absence of movements), rigidity (a resistance to imposed movement),
disequilibrium (impaired balance); and limb dystonia (abnormal muscle postures). Other
symptoms such as cognitive and visual-spatial impairments, apraxia (loss of the ability to make
familiar, purposeful movements), hesitant and halting speech, myoclonus (muscular jerks), and
dysphagia (difficulty swallowing) may also occur. An individual with CBD eventually becomes
unable to walk.
CBD is a sporadic neurodegenerative process related to abnormal aggregation of hyperphos‐
phorylated tau protein.  This  disease  is  associated with abnormal  insoluble  tau isoforms
with  four  conserved  repeat  sequences  (4R  tau).  Neuropathological  criteria  for  CBD
emphasize  the  histopathological  findings  of  tau-immunoreactive  lesions  in  addition  to
ballooned neurons,  cortical  atrophy,  and nigral  degeneration.  The  ballooned achromatic
neurons, were once emphasized as a major component of the histopathology and gave the
disorder its original name. Abnormal tau immunoreactivity is found in both the neurons
and the glia. In neurons, tau immunohistochemistry reveals diffuse or granular cytoplas‐
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mic staining, pre-tangles, and small neurofibrillary tangles. These probably account for the
corticobasal  inclusions found in subcortical  gray matter regions including the substantia
nigra.  tau immunoreactive  threads in  both neurons and glia  are  numerous in  gray and
white matter. CBD pathology includes astrocytic plaques with tau deposition largely in the
distal processes of astrocytes. These astrocytic plaques are distinct from tufted astrocytes
found in PSP, where tau is deposited more proximally to the cell body as well as in distal
processes. Both CBD and PSP had in common oligodendroglial inclusions, coiled bodies,
and threads, although the astrocytic changes can distinguish between the two disease (CBD
or PSD). In addition, while threads are numerous and diffuse in CBD, they are rarely seen
in  the  cerebral  cortices  in  PSP,  although  they  may  be  dense  in  other  areas.  A  recent
neuropathological  study  has  discovered  the  presence  of  TAR-DNA-binding  protein  43
(TDP-43) in a subset of patients with CBD pathology. There was no clear clinical correla‐
tion with the presence of TDP-43 inclusions in CBD [67].
12. Progressive supranuclear palsy
Progressive supranuclear palsy affects men and women equally and in most cases it appears
as a atypical parkinsonism with axial rigidity, postural instability and unexplained falls, with
most patients also developing progressive vertical gaze palsy (for which the disorder is
named), dysarthria and dysphagia [68] PSP has asymmetric cortical atrophy and can clinically
mimic CBS. The pathologic diagnosis is made by the microscopic findings of globose neuro‐
fibrillary tangles and variable neuron loss with gliosis of the globus pallidus, subthalamic
nucleus, periaqueductal grey matter of pons, and substantia nigra. Mutant tau protein is
present in inclusions [69, 70].
Whereas 4R tau is characteristic of corticobasal degeneration (CBD) and progressive supra‐
nuclear palsy. Diagnosis rests upon postmortem examination of the brain and demonstration
of globose tangles, oligodendroglial coiled bodies and tufted astrocytes. The core neuroana‐
tomical regions affected in all cases of PSP include the basal ganglia, subthalamic nucleus and
the substantia nigra. Cortical involvement is greatest in motor and premotor cortices. Pathol‐
ogy of the cerebellar dentate nucleus and the cerebellar outflow pathway (dentato-rubro-
thalamic pathway) is usually severe and associated with profound atrophy of the superior
cerebellar peduncle.
13. Conclusion
This review, gives a neuropathological approach towards finding biomarkers for dementia.
However, finding the optimal biomarker for each neurodegenerative disease is still in an
experimental face. In the case of AD, it is required far deeper molecular and immunohisto‐
chemical studies of abnormal tau posttranslational modifications (i.e. phosphorylation and
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truncation) and better understanding of its contribution to the development of dementia,
particularly, it is important to understand the role of the paired helical filaments, that accu‐
mulate in the neuronal soma, promoting degeneration and cell death. Of relevance is to
consider that in other dementias such as tauopathies, tau protein processing resembles the
initial steps in AD, although there is no well-defined neuropathological impact of tau aggre‐
gation in lesions such as Pick bodies, Lewy bodies, as well as the presence of tau in NFTs and
glial cells in CBD and PSP. Therefore, all efforts should be focused on determining reliable
biomarkers for each of the dementias with the aim of generating new improved diagnostic
approaches for early detection of these neurodegenerative diseases.
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